Dana-Farber Cancer Institute presented Phase 2 CAR-PRISM results using CAR T-cell therapy in high-risk smoldering multiple myeloma (SMM), reporting durable and profound responses across participants. The study evaluated CAR T at an earlier disease stage—before progression to active myeloma—aiming to prevent or delay transformation. The program is notable because it tests immune interception in a population where deep molecular responses could shift treatment goals from long-term control to potential disease eradication, a concept that remains difficult to achieve with standard approaches. The report highlights responses that were both durable and extensive. If these results are confirmed in broader datasets, the clinical development path for CAR T could continue moving upstream into earlier stages of disease where therapy sequencing and toxicity management become critical.